Abstract: The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotides comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene contructs.
Abstract: Oligonucleotides capable of inhibiting the production of proliferation-associated proteins are provided. Oligonucleotides designed to be hybridizable with nucleic acids encoding nucleolar proteins are believed to be therapeutically useful. Certain of such oligonucleotides, hybridizable to portions of the gene coding for p120, especially the 3' untranslated region, were made and found to inhibit the synthesis of p120. The oligonucleotides of the invention are useful for the treatment of diseases characterized by hyperproliferation of cells such as malignancies, inflammatory and cardiovascular diseases. Treatment of human breast cell carcinoma, human epitheloid cervix carcinoma, human amelanotic melanoma, human renal cell carcinoma and other tumors are indicated.
Type:
Grant
Filed:
November 18, 1994
Date of Patent:
August 12, 1997
Assignees:
Baylor College of Medicine, ISIS Pharmaceuticals, Inc.
Inventors:
Harris Busch, Clarence Frank Bennett, Laszlo Perlaky, Yasuo Saijo, Rose K. Busch
Abstract: The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene constructs.
Abstract: This invention relates to methods of eliciting an immune response and/or protective immunity in a vertebrate by introducing into the vertebrate a DNA vaccine which consists essentially of DNA encoding an antigen or antigens, e.g., capsid proteins or polypeptides, of rotavirus. The uptake of the DNA vaccine by a host vertebrate results in the expression of the capsid protein, thereby eliciting humoral or cell-mediated immune responses, or both, which can provide protection against infection and/or prevent clinically significant rotavirus-caused disease. In addition, the invention demonstrates that an internal vital antigen provides protective immunity in a host. The host can be any vertebrate, including birds, piglets, and humans.
Type:
Grant
Filed:
April 20, 1995
Date of Patent:
April 15, 1997
Assignee:
University of Massachusetts Medical Center
Inventors:
John E. Herrmann, Harriet L. Robinson, Ellen F. Fynan
Abstract: The invention encompasses tumorigenicity-inhibiting antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprises the tumorigenicity-inhibiting antisense nucleotide.